A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk

Juhan Lee, Jung Jun Lee, Beom Seok Kim, Jae Geun Lee, Kyu Ha Huh, Yongjung Park, Yu Seun Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The optimal immunosuppressive strategy for renal transplant recipients at high immunologic risk remains a topic of investigation. This prospective single arm pilot study was undertaken to evaluate the safety and efficacy of a combined tacrolimus and sirolimus regimen in recipients at immunological high risk and to compare outcomes with a contemporaneous control group received tacrolimus and mycophenolate mofetil. Patients that received a renal allograft between 2010 and 2011 at high risk (defined as panel reactive antibodies > 50%, 4 or more human leukocyte antigen mismatches, or retransplantation) were enrolled. All patients received basiliximab induction and corticosteroids. A total of 28 recipients treated with tacrolimus and sirolimus were enrolled in this study and 69 recipients were retrospectively reviewed as a control group. The sirolimus group showed a higher, but not statistically significant, incidence of biopsy proven acute rejection and a lower glomerular filtration rate than the control group. Furthermore, sirolimus group was associated with significant increases in BKV infection (P = 0.031), dyslipidemia (P = 0.004), and lymphocele (P = 0.020). The study was terminated prematurely due to a high incidence of adverse events. A de novo tacrolimus/sirolimus combination regimen may not be an ideal choice for recipients at high immunological risk.

Original languageEnglish
Pages (from-to)682-687
Number of pages6
JournalJournal of Korean medical science
Volume30
Issue number6
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Tacrolimus
Sirolimus
Arm
Kidney
Safety
Control Groups
Lymphocele
Mycophenolic Acid
Incidence
Immunosuppressive Agents
Dyslipidemias
HLA Antigens
Glomerular Filtration Rate
Allografts
Adrenal Cortex Hormones
Transplant Recipients
Biopsy
Antibodies
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{f49b079d22474029af698a5607368294,
title = "A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk",
abstract = "The optimal immunosuppressive strategy for renal transplant recipients at high immunologic risk remains a topic of investigation. This prospective single arm pilot study was undertaken to evaluate the safety and efficacy of a combined tacrolimus and sirolimus regimen in recipients at immunological high risk and to compare outcomes with a contemporaneous control group received tacrolimus and mycophenolate mofetil. Patients that received a renal allograft between 2010 and 2011 at high risk (defined as panel reactive antibodies > 50{\%}, 4 or more human leukocyte antigen mismatches, or retransplantation) were enrolled. All patients received basiliximab induction and corticosteroids. A total of 28 recipients treated with tacrolimus and sirolimus were enrolled in this study and 69 recipients were retrospectively reviewed as a control group. The sirolimus group showed a higher, but not statistically significant, incidence of biopsy proven acute rejection and a lower glomerular filtration rate than the control group. Furthermore, sirolimus group was associated with significant increases in BKV infection (P = 0.031), dyslipidemia (P = 0.004), and lymphocele (P = 0.020). The study was terminated prematurely due to a high incidence of adverse events. A de novo tacrolimus/sirolimus combination regimen may not be an ideal choice for recipients at high immunological risk.",
author = "Juhan Lee and Lee, {Jung Jun} and Kim, {Beom Seok} and Lee, {Jae Geun} and Huh, {Kyu Ha} and Yongjung Park and Kim, {Yu Seun}",
year = "2015",
month = "1",
day = "1",
doi = "10.3346/jkms.2015.30.6.682",
language = "English",
volume = "30",
pages = "682--687",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "6",

}

A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk. / Lee, Juhan; Lee, Jung Jun; Kim, Beom Seok; Lee, Jae Geun; Huh, Kyu Ha; Park, Yongjung; Kim, Yu Seun.

In: Journal of Korean medical science, Vol. 30, No. 6, 01.01.2015, p. 682-687.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk

AU - Lee, Juhan

AU - Lee, Jung Jun

AU - Kim, Beom Seok

AU - Lee, Jae Geun

AU - Huh, Kyu Ha

AU - Park, Yongjung

AU - Kim, Yu Seun

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The optimal immunosuppressive strategy for renal transplant recipients at high immunologic risk remains a topic of investigation. This prospective single arm pilot study was undertaken to evaluate the safety and efficacy of a combined tacrolimus and sirolimus regimen in recipients at immunological high risk and to compare outcomes with a contemporaneous control group received tacrolimus and mycophenolate mofetil. Patients that received a renal allograft between 2010 and 2011 at high risk (defined as panel reactive antibodies > 50%, 4 or more human leukocyte antigen mismatches, or retransplantation) were enrolled. All patients received basiliximab induction and corticosteroids. A total of 28 recipients treated with tacrolimus and sirolimus were enrolled in this study and 69 recipients were retrospectively reviewed as a control group. The sirolimus group showed a higher, but not statistically significant, incidence of biopsy proven acute rejection and a lower glomerular filtration rate than the control group. Furthermore, sirolimus group was associated with significant increases in BKV infection (P = 0.031), dyslipidemia (P = 0.004), and lymphocele (P = 0.020). The study was terminated prematurely due to a high incidence of adverse events. A de novo tacrolimus/sirolimus combination regimen may not be an ideal choice for recipients at high immunological risk.

AB - The optimal immunosuppressive strategy for renal transplant recipients at high immunologic risk remains a topic of investigation. This prospective single arm pilot study was undertaken to evaluate the safety and efficacy of a combined tacrolimus and sirolimus regimen in recipients at immunological high risk and to compare outcomes with a contemporaneous control group received tacrolimus and mycophenolate mofetil. Patients that received a renal allograft between 2010 and 2011 at high risk (defined as panel reactive antibodies > 50%, 4 or more human leukocyte antigen mismatches, or retransplantation) were enrolled. All patients received basiliximab induction and corticosteroids. A total of 28 recipients treated with tacrolimus and sirolimus were enrolled in this study and 69 recipients were retrospectively reviewed as a control group. The sirolimus group showed a higher, but not statistically significant, incidence of biopsy proven acute rejection and a lower glomerular filtration rate than the control group. Furthermore, sirolimus group was associated with significant increases in BKV infection (P = 0.031), dyslipidemia (P = 0.004), and lymphocele (P = 0.020). The study was terminated prematurely due to a high incidence of adverse events. A de novo tacrolimus/sirolimus combination regimen may not be an ideal choice for recipients at high immunological risk.

UR - http://www.scopus.com/inward/record.url?scp=84952669250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952669250&partnerID=8YFLogxK

U2 - 10.3346/jkms.2015.30.6.682

DO - 10.3346/jkms.2015.30.6.682

M3 - Article

C2 - 26028917

AN - SCOPUS:84952669250

VL - 30

SP - 682

EP - 687

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 6

ER -